It is worth noting that the success of anti-PD-1/PD-L1 therapy depends not only on positive PD-L1 expression but also on CD8+ tumor-infiltrating lymphocyte density and the ability of CD8+ T cells to recognize tumor antigens (55, 63). This evidence concerns the gene CD8A and neoplasm.